Vaxil Retains Investor Engagement and Marketing Firm

Not for distribution by US newswire or in United States

NESS-ZIONA, Israel, Dec. 22, 2020 (GLOBE NEWSWIRE) — VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that the Company has engaged Toronto-based marketing firm North Equities Corp. (“North Equities” or “NE”) that specializes in various social media platforms, to facilitate greater investor engagement and widespread dissemination of the Company’s news.

In addition to press releases, the Company will be posting important information and updates through videos from the official Company Youtube channel.

You can also access these videos from Vaxil’s website: http://vaxil-bio.com/ 

“We have listened to our shareholders and following our recently completed private placement, we believe that we are in a position to hire a solid and innovative marketing firm that can help us tell our story better,” said David Goren, Vaxil’s Chairman and Chief Executive Officer, and continued, “We started the year with the discovery that we may be able to significantly contribute to the fight against COVID-19 followed by preclinical experiments on our potential COVID-19 vaccine candidate. We are ending the year with the launch of our USAMRIID collaboration to test the potential vaccine candidate’s ability to prevent COVID-19 in animals, as well the closing of a private placement, which together with proceeds from the exercise of warrants that took place earlier in the year, provides us with enough cash to continue to work towards fulfilling milestones for our shareholders in 2021.”

Jason Coles, CEO at North Equites expressed his confidence in North Equities’s ability to create value for Vaxil stakeholders: “We are very excited to be able to enhance Vaxil’s exposure during this significant period in the Company’s life cycle. Through our marketing capabilities on social media platforms, we intend to widen the communication outreach while providing up to date information about the Company to a bigger audience.” 

About North Equities: The North Equities team has more than 100 team-years of equity experience and has helped more than 200 companies acquire more than 120k+ investors combined. With the perfect combination of expertise, tactics, and a track record in fundraising and marketing, North Equities has created the next evolution of investor engagement and marketing. 

ABOUT VAXIL 
Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin™, CorVax™  and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease vaccines and treatments alone and in combination with other treatments.

Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach. These signal peptides induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells. 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Disclaimer: The Company cautions that COVID-19 Vaccine Development is still under early stage research and development and is not making any express or implied claims that it has the ability to eliminate the COVID-19 virus at this time. The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities — that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.

CONTACT INFORMATION
For further information please visit http://vaxil-bio.com/ or contact:
North Equities, info@northequities.com
David Goren, CEO — info@vaxil-bio.com, +972 (52) 720-6000